| pubmed-article:8772639 | pubmed:abstractText | Fluorine-18-6-fluoro-L-Dopa (F-Dopa) has been used successfully to evaluate striatal dopaminergic function in humans. The kinetic analysis of F-Dopa studies, however, is confounded by the presence of [18F]6-fluoro-3-O-methyl-L-Dopa (OMFD), the major metabolite of F-Dopa formed in the periphery that crosses the blood-brain barrier. We present results of compartmental analysis in subjects in whom we independently measured the kinetics of OMFD in the blood and striatum, and used this knowledge to solve for the kinetics of F-Dopa. | lld:pubmed |
